Skip to content

K A Kovar

3 papers in the library · publishing 1993-2001

Papers

Sort Most recent Most cited

Enantio-selective cognitive and brain activation effects of N-ethyl-3,4-methylenedioxyamphetamine in humans.

Neuropharmacology August 2001 M Spitzer, B Franke, H Walter et al.

In a randomised double-blind trial the subjective, neuropsychological and brain activation effects of the two enantiomers of the MDMA (ecstasy-) like drug N-ethyl-3,4-methylenedioxyamphetamine (MDE) were studied in five normal subjects using functional magnetic resonance imaging (fMRI). (S)-MDE produced elevated mood, impairments in conceptually driven cognition and marked right frontal...

Neuroendocrine and cardiovascular effects of MDE in healthy volunteers.

Neuropsychopharmacology May 1993 E Gouzoulis, U Von Bardeleben, A Rupp et al.

The drug 3,4-methylenedioxyethamphetamine ([MDE] also known as "Eve") is a less toxic analog of 3,4-methylenedioxymethamphetamine (also known as "Ecstasy") with similar psychotropic effects in humans. In a double-blind placebo-controlled, cross-over study we administered 140 mg of MDE or placebo orally to eight healthy male volunteers at 1:30 P.M. Serum cortisol, prolactin (PRL), and growth...

Psychological effects of MDE in normal subjects. Are entactogens a new class of psychoactive agents?

Neuropsychopharmacology February 1993 L Hermle, M Spitzer, D Borchardt et al.

The so-called entactogens 3,4-methylenedioxymethamphetamine ([MDMA] also known as "Ecstasy," or "Adam") and its analog 3,4-methylenedioxyethamphetamine ([MDE] also known as "Eve") exert similar psychotropic effects in humans. Two double-blind placebo-controlled psychometric studies with normal control subjects were conducted. Placebo or MDE (140 mg) was administered orally to eight male...